Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

FerGene (Ferring / Blackstone Life Sciences)

FerGene, a new gene therapy company and Ferring subsidiary, has been created to potentially commercialize nadofaragene firadenovec in the U.S. and to advance the global clinical development. FerGene’s goal is to bring this promising therapy to a patient population which has seen little improvement in their standard of care over the past twenty years. Blackstone Life Sciences will invest $400 million USD and Ferring will invest up to $170 million USD in FerGene. Ferring will also potentially launch and commercialize nadofaragene firadenovec outside of the U.S. *


Period Start 2019-11-25 established jv
  Group Ferring (Paulsen Foundation) (Group)
Products Industry nadofaragene firadenovec (rAd-IFN/Syn3)
  Industry 2 drug development
  City n. a. 
    Address record changed: 2019-11-27
Basic data Employees n. a.
    * Document for �About Section�: Ferring Pharmaceuticals S.A.. (12/5/19). "Press Release: FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint". Washington, DC.
Record changed: 2020-04-27


Picture [iito] Plain Stupid Simple 650x80px

More documents for Ferring (Paulsen Foundation) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top